Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma, Inc. (CBIO)
:CBIO
Total Valuation
Crescent Biopharma has a market cap or net worth of $172.68M. The enterprise value is $7.94M.
Market Cap$172.68M
Enterprise Value$7.94M
Share Statistics
Crescent Biopharma has 13,892,562 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,892,562
Owned by Insiders0.45%
Owned by Institutions―
Financial Efficiency
Crescent Biopharma’s return on equity (ROE) is -7.13 and return on invested capital (ROIC) is -596.80%.
Return on Equity (ROE)-7.13
Return on Assets (ROA)-3.42
Return on Invested Capital (ROIC)-596.80%
Return on Capital Employed (ROCE)-6.12
Revenue Per Employee0.00
Profits Per Employee-1.15M
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crescent Biopharma is ―. Crescent Biopharma’s PEG ratio is -24.58.
PE Ratio―
PS Ratio0.00
PB Ratio302.15
Price to Fair Value302.15
Price to FCF-51.61
Price to Operating Cash Flow-2.65
PEG Ratio-24.58
Income Statement
In the last 12 months, Crescent Biopharma had revenue of 0.00 and earned -37.88M in profits. Earnings per share was -0.59.
Revenue0.00
Gross Profit-35.17K
Operating Income-32.51M
Pretax Income-37.88M
Net Income-37.88M
EBITDA-37.84M
Earnings Per Share (EPS)-0.59
Cash Flow
In the last 12 months, operating cash flow was -27.41B and capital expenditures -10.10M, giving a free cash flow of -27.42B billion.
Operating Cash Flow-27.41B
Free Cash Flow-27.42B
Free Cash Flow per Share-1.97K
Dividends & Yields
Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―
Dividend Per Share$0.24
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.25
52-Week Price Change-26.45%
50-Day Moving Average13.12
200-Day Moving Average20.85
Relative Strength Index (RSI)47.62
Average Volume (3m)125.30K
Important Dates
Crescent Biopharma upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateMay 1, 2025
Next Earnings DateApr 30, 2026
Ex-Dividend DateJan 13, 2023
Financial Position
Crescent Biopharma as a current ratio of 1.92, with Debt / Equity ratio of 1.18%
Current Ratio1.92
Quick Ratio1.92
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Crescent Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Crescent Biopharma EV to EBITDA ratio is -42.14, with an EV/FCF ratio of -51.27.
EV to Sales0.00
EV to EBITDA-42.14
EV to Free Cash Flow-51.27
EV to Operating Cash Flow-51.28
Balance Sheet
Crescent Biopharma has $152.65M in cash and marketable securities with $1.64M in debt, giving a net cash position of $151.00M billion.
Cash & Marketable Securities$152.65M
Total Debt$1.64M
Net Cash$151.00M
Net Cash Per Share$10.87
Tangible Book Value Per Share$0.08
Margins
Gross margin is 95.70%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin95.70%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Crescent Biopharma is $25.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.60
Price Target Upside105.95% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast-0.58%